Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GlycoMimetics Inc | GLYC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.80 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.11 - 3.5299 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.80 | USD |
GlycoMimetics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
180.3M | 64.39M | - | 75k | -46.69M | -0.73 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GlycoMimetics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLYC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.52 | 2.87 | 2.50 | 2.64 | 327,463 | 0.28 | 11.11% |
1 Month | 3.20 | 3.36 | 2.50 | 2.84 | 277,586 | -0.40 | -12.50% |
3 Months | 2.56 | 3.5299 | 2.20 | 2.97 | 341,878 | 0.24 | 9.37% |
6 Months | 1.41 | 3.5299 | 1.11 | 2.49 | 243,441 | 1.39 | 98.58% |
1 Year | 1.39 | 3.5299 | 1.11 | 2.11 | 222,172 | 1.41 | 101.44% |
3 Years | 3.37 | 4.16 | 0.51 | 2.13 | 438,490 | -0.57 | -16.91% |
5 Years | 12.55 | 13.56 | 0.51 | 3.15 | 475,198 | -9.75 | -77.69% |
GlycoMimetics Description
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. |